Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis
Authors:
Open Access
- 1 November 2020
- journal article
- review article
- Published by Elsevier in eClinicalMedicine
- Vol. 28, 100573
Abstract
No abstract availableKeywords
Funding Information
- World Health Organization
This publication has 39 references indexed in Scilit:
- Dolutegravir in antiretroviral-naive adults with HIV-1AIDS, 2013
- STAR Study: single tablet regimen emtricitabine/rilpivirine/tenofovir DF is non-inferior to efavirenz/emtricitabine/tenofovir DF in ART-naïve adultsJournal of the International AIDS Society, 2012
- Evidence Synthesis for Decision Making 2Medical Decision Making, 2012
- Scale-up of HIV Treatment Through PEPFARJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- GRADE guidelines: 9. Rating up the quality of evidenceJournal of Clinical Epidemiology, 2011
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)Journal of Clinical Epidemiology, 2011
- Efavirenz versus Boosted Atazanavir or Zidovudine and Abacavir in Antiretroviral Treatment–Naive, HIV‐Infected Subjects: Week 48 Data from the Altair StudyClinical Infectious Diseases, 2010
- Checking consistency in mixed treatment comparison meta‐analysisStatistics in Medicine, 2010
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008